Page last updated: 2024-12-06

vindesine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Vindesine: Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS). [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11643449
CHEMBL ID238071
SCHEMBL ID13524311
MeSH IDM0022680
PubMed CID40839
CHEMBL ID219146
CHEBI ID36373
SCHEMBL ID4420
MeSH IDM0022680

Synonyms (62)

Synonym
compound 112531
desacetylvinblastine amide
3-carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
53643-48-4
3-(aminocarbonyl)-o4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
DB00309
3-(aminocarbonyl)-o(sup 4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
hsdb 6961
vincaleukoblastine, 3-(aminocarbonyl)-o(sup 4)-deacetyl-3-de(methoxycarbonyl)-
einecs 258-682-2
lilly 112531
vindesina [inn-spanish]
vindesinum [inn-latin]
vincaleukoblastine, 23-amino-o(sup 4)-deacetyl-23-demethoxy-
vindesina
unii-rsa8ko39wh
vindesinum
vindesine [usan:inn:ban]
rsa8ko39wh ,
vindesine [who-dd]
vindesine [hsdb]
vindesine [vandf]
vindesine [inn]
compound-112531
vindesine [usan]
vindesine [mi]
SCHEMBL13524311
CHEMBL238071
methyl (13s,15r,17s)-13-[(1r,9r,10s,11r,12r,19r)-10-carbamoyl-12-ethyl-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(1
EN300-33412062
methyl (13s,15r,17s)-13-[(1r,9r,10s,11r,12r,19r)-10-carbamoyl-12-ethyl-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.0^{1,9}.0^{2,7}.0^{16,19}]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.0^{4,12}.0^{5,1
AB01275494-01
methyl (5s,7s,9s)-9-[(2b,3b,4b,5a,12b,19a)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2h-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate
3-(aminocarbonyl)-o(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
methyl (5s,7s,9s)-9-[(2beta,3beta,4beta,5alpha,12beta,19alpha)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2h-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate
CHEBI:36373 ,
3-carbamoyl-o(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
vindesine (usan/inn)
D06304
vindesine
desacetylvinblastine amide sulfate
vincaleukoblastine, 3-(aminocarbonyl)-o4-deacetyl-3-de(methoxycarbonyl)-
HMS2090E15
CHEMBL219146
BRD-K59753975-065-01-3
AB00698294-03
SCHEMBL4420
Q-100607
DTXSID6023739
methyl (13s,15s,17s)-13-[(1r,9r,10s,11r,12r,19r)-10-carbamoyl-12-ethyl-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.0^{1,9}.0^{2,7}.0^{16,19}]nonadeca-2(7),3,5,13-tetraen-4-yl]-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.0^{4,12}.0^{
HHJUWIANJFBDHT-KOTLKJBCSA-N
EX-A3837
Q416660
STL565153
hanoazacycloundecino[5,4-b]indole-9-carboxylate
methyl (5s,7s,9s)-9-[(2beta,3beta,4beta,5alpha,12beta,19alpha)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2h-3,7-met
compound 112531;
AKOS037623357
AC-36879
HY-16514
methyl (13s,15s,17s)-13-[(1r,9r,10s,11r,12r,19r)-10-carbamoyl-12-ethyl-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(1
FS-7032

Research Excerpts

Overview

Vindesine (VDS) is a new vinca-alkaloid related to vinblastine and vincristine. It blocks production of the microtubules in the mitotic phase of the cell cycle.

ExcerptReferenceRelevance
"Vindesine is a new vinca alkaloid antineoplastic agent derived from vinblastine. "( Pharmacology, clinical efficacy and adverse effects of vindesine sulfate, a new vinca alkaloid.
Bromer, R; Cersosimo, RJ; Hong, WK; Licciardello, JT,
)
1.82
"Vindesine (VDS) is a new vinca-alkaloid related to vinblastine and vincristine that blocks production of the microtubules in the mitotic phase of the cell cycle. "( Inhibition of murine CFU-C by vindesine: restoration of colony growth by colony stimulating factor.
Caramatti, C; Degliantoni, G; Mangoni, L; Pigoli, G; Rizzoli, V, 1983
)
2
"Vindesine (VDS) is a new semisynthetic vinca alkaloid which has demonstrated therapeutic activity against a variety of solid tumors. "( Vindesine in the treatment of malignant mesothelioma: a phase II study.
Cheng, E; Gralla, R; Kelsen, D; Martini, N, 1983
)
3.15
"Vindesine is a recent vinca alkaloid derivative with anti-tumor effects shown in in vitro systems and in patients with acute lymphocytic leukemia (ALL)."( Vindesine and prednisone for remission induction in children with acute lymphocytic leukemia.
Klopovich, P; Mehta, P; Smith, SD; Trueworthy, RC; Vats, TS, 1981
)
2.43
"Vindesine is a semisynthetic vinca alkaloïd. "( [Continuous 5-day vindesine in the treatment of leukemias and lymphomas (author's transl)].
Carcassonne, Y; Gastaut, JA; Maraninchi, D; Tubiana, N, 1981
)
2.04
"Vindesine (VDS) is an analogue of the vinca alkaloids. "( Vindesine: a new vinca alkaloid.
Bayssas, M; de Vassal, F; Gouveia, J; Hayat, M; Jasmin, C; Mathé, G; Misset, JL; Musset, M; Ribaud, P; Schwarzenberg, L, 1980
)
3.15
"Vindesine/Cis-Platinum is an alternativ scheme to Bleomycin combinations; even after prior RT and CT tumorreduction is frequent."( [Chemotherapy of head and neck squamous cell cancer with vindesine (Eldesine) and cis-platinum (Platinex) (author's transl)].
Ross, H; Ruffmann, R; Seifert, R; Sturm, E, 1982
)
1.23
"Vindesine is a semisynthetic derivative of vinblastine which has been evaluated in clinical studies since the late 1970's. "( Is there a role for vindesine in the treatment of non-small cell lung cancer?
Hansen, HH; Sørensen, JB,
)
1.9
"Vindesine is a satisfactory stathmokinetic agent, but in view of its greater cost offers no particular advantages over vincristine."( Vindesine as a stathmokinetic agent in human rectal tumours in organ culture.
Appleton, DR; Pritchett, CJ; Senior, PV; Sunter, JP; Watson, AJ; Wilson, RG, 1985
)
2.43

Effects

Vindesine has modest activity against non-small cell carcinoma of the bronchus. It may be more effective than vincristine, with similar toxicity.

ExcerptReferenceRelevance
"Vindesine has modest activity against non-small cell carcinoma of the bronchus and may be more effective than vincristine, with similar toxicity."( Comparison of vincristine and vindesine in the treatment of inoperable non-small cell bronchial carcinoma.
Geddes, DM; Harper, PG; Jewkes, J; Souhami, RL; Spiro, SG; Tobias, JS, 1983
)
1.28
"Vindesine has minor but real activity in this group of patients with advanced head and neck cancer who have not received prior chemotherapy."( Phase II trial of vindesine in patients with squamous cell cancer of the head and neck.
Clark, GM; Griffin, C; Mattox, DE; Sledge, GW; Von Hoff, DD, 1984
)
1.32

Treatment

Vindesine pretreatment resulted in an enhanced killing of spermatogonial cells at day 2 post-exposure. The treatment with vindesine was generally well tolerated. In five out of 130 patients (3.8%) the treatment was discontinued due to convulsion.

ExcerptReferenceRelevance
"Vindesine pretreatment resulted in an enhanced killing of spermatogonial cells at day 2 post-exposure at all the exposure doses, except 3 Gy when compared to DDW + irradiated controls."( Effect of vindesine sulfate on the radiation-induced alterations in mouse spermatogenesis: a flow cytometric evaluation.
Jagetia, GC; Jyothi, P; Krishnamurthy, H, 1998
)
1.42
"The treatment with vindesine was generally well tolerated, although in five out of 130 patients (3.8%) the treatment was discontinued due to convulsion, feeling of abdominal distention plus constipation, paralytic ileus, dysuria plus constipation, or interstitial pneumonia."( [Phase II study of vindesine in hematological malignancies].
, 1983
)
0.91
"Treatment with vindesine (0.1 mg/kg/week i.p."( Effects of alpha-difluoromethylornithine alone and combined with adriamycin or vindesine on L1210 leukemia in mice, EMT6 solid tumors in mice, and solid tumors induced by injection of hepatoma tissue culture cells in rats.
Bartholeyns, J; Koch-Weser, J, 1981
)
0.83

Toxicity

The replacement of vindesine with vincristine in mR-ACVBP seems feasible, with manageable adverse events and excellent 2-year progression-free survival. Vindesine combined with human immunoglobulin is an effective and safe treatment option for pediatric ITP.

ExcerptReferenceRelevance
" Vindesine was more toxic than Vincristine."( A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse. A Pediatric Oncology Group study.
Beardsley, GP; Buchanan, G; Hvizdale, E; Krischer, J; Link, M; Maybee, D; Mehta, P; Nitschke, R; Ragab, A; Vats, T, 1992
)
1.44
" On an equal weight basis, VCR proved to be significantly more toxic than either VBL or VDS (P less than ."( Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse.
Alberts, DS; Dorr, RT, 1985
)
0.27
" The results indicate that the intracellular concentrations combined with the intrinsic sensitivities of each cell line to etretinate and vindesine determines the toxic response."( Cytotoxicity of etretinate and vindesine.
Gaukroger, JM; MacKie, R; Wilson, L, 1985
)
0.76
" Continuous exposure of cultured 791T cells indicated that the vindesine was partially inactivated following conjugation since the conjugate was less toxic than the free drug."( Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugate.
Baldwin, RW; Embleton, MJ; Jacobs, E; Marsden, CH; Rowland, GF; Simmonds, RG, 1983
)
0.75
" Significant hematological toxicity was documented but the most serious adverse event was the occurrence of 18 (10%) cardiac or sudden deaths."( A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancer.
Berchier, MC; Bureau, G; Dabouis, G; Klastersky, J; Libert, P; Ries, F; Schmerber, J; Sculier, JP; Thiriaux, J; Van Cutsem, O, 1994
)
0.53
" The most serious adverse event was the occurrence of 18 (10%) cardiac or sudden deaths."( A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5-fluorouracil. A regimen associated with major toxicity in patients with advanced non-small lung cancer. European Lung Cancer Working Party.
Berchier, MC; Bureau, G; Dabouis, G; Klastersky, J; Libert, P; Ries, F; Schmerber, J; Sculier, JP; Thiriaux, J; Van Cutsem, O, 1994
)
0.53
" However, the induction phase is toxic and a 3-weekly interval appears more appropriate."( Feasibility, toxicity, and activity of LNH84-derived chemotherapy in the management of aggressive lymphomas.
Alberto, P; Bauer, J; Iten, PA; Laurencet, FM; Mermillod, B; Zulian, GB, 1997
)
0.3
"This complex and highly toxic chemoimmunotherapeutic regimen should not be considered as standard therapy in patients with metastatic malignant melanoma."( Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?
Hofmann, MA; Sterry, W; Trefzer, U, 2007
)
0.34
" No severe adverse effects were observed in both groups."( [Efficacy and safety of rhTPO in the treatment of pediatric primary immune thrombocytopenia].
Chen, Y; Fu, R; Huang, Y; Liu, W; Liu, X; Xue, F; Yang, R; Zhang, L, 2015
)
0.42
"For pediatric ITP, rhTPO has a similar outcomes with vindesine combined with human immunoglobulin, and it is an effective and safe treatment option."( [Efficacy and safety of rhTPO in the treatment of pediatric primary immune thrombocytopenia].
Chen, Y; Fu, R; Huang, Y; Liu, W; Liu, X; Xue, F; Yang, R; Zhang, L, 2015
)
0.67
" The most common adverse events during induction were anemia (91%), febrile neutropenia (64%; grade 4 in 46%), thrombocytopenia (39%), and mucositis (21%)."( Safety and Efficacy of Replacing Vindesine with Vincristine in R-ACVBP Regimen for the Treatment of Large B Cell Lymphomas.
Abou Dalle, I; Al Chami, F; Bazarbachi, A; Charafeddine, M; El Cheikh, J; El Darsa, H; El Sayed, R; Ibrahim, A; Kort, J, 2021
)
0.9
"The replacement of vindesine with vincristine in mR-ACVBP seems feasible, with manageable adverse events and excellent 2-year progression-free survival."( Safety and Efficacy of Replacing Vindesine with Vincristine in R-ACVBP Regimen for the Treatment of Large B Cell Lymphomas.
Abou Dalle, I; Al Chami, F; Bazarbachi, A; Charafeddine, M; El Cheikh, J; El Darsa, H; El Sayed, R; Ibrahim, A; Kort, J, 2021
)
1.23

Pharmacokinetics

ExcerptReferenceRelevance
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Pharmacokinetic parameters of BHAC in uremia were not different from that in patients with normal renal function, and hemodialysis did not affect on the plasma level of BHAC."( [Pharmacokinetics of BHAC, VP-16 and Ara-C derived from BHAC in a hemodialysed patient with AMMoL].
Kaito, K; Katayama, T; Kobayashi, M; Masuoka, H; Nishiwaki, K; Ochiai, S; Saito, A; Shimada, T; Watanabe, R; Yoshida, M, 1991
)
0.28
" This observation was interpreted as an indication of VDS pharmacokinetic nonlinearity."( Clinical pharmacokinetics of vindesine infusion.
Barbet, J; Cano, JP; Kleisbauer, JP; Martin, M; Rahmani, R,
)
0.42
" The linearity and the reproducibility of CPH kinetics were confirmed and its pharmacokinetic parameters were found to be unaffected by simultaneous or sequential administration of either vindesin or cisplatin."( Pharmacokinetics of cyclophosphamide administered alone or in combination with vindesin or cisplatin in 5 patients with bronchial adenocarcinoma.
Berger, JA; Chabard, JL; Chollet, P; Lartigue-Mattei, C; Petit, J; Plagne, R; Touzet, C, 1988
)
0.27
" The plasma pharmacokinetic and CSF influx of MTX and VDS were assayed after high dose systemic MTX with an intravenous bolus of VDS administered in the treatment of acute lymphoblastic leukemia."( Methotrexate-vindesine association in leukemia: pharmacokinetic study.
Barbet, J; Cano, JP; Gastaut, JA; Imbert, AM; Lejeune, C; Lena, N; Maraninchi, D; Sainty, D; Sebahoun, G; Tubiana, N, 1985
)
0.64
" Pharmacokinetic modeling, assuming a prolonged infusion period, resulted in a triphasic decay curve, with an extremely short distribution phase which would not be clinically detectable."( Pharmacokinetics of vindesine given as an intravenous bolus and 24-hour infusion in humans.
Andrejczuk, A; Holland, JF; Norton, L; Ohnuma, T, 1985
)
0.59
" Pharmacokinetic data were analyzed by a non-linear least-square regression program NONLIN, and the data fit a two-compartment open model."( Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys.
Sethi, VS; Spurr, CL; Surratt, P, 1984
)
0.52
" However, vincristine had a longer and more variable terminal phase half-life (85 +/- 69 hr) than vindesine (24 +/- 10 hr) or vinblastine (25 +/- 7 hr)."( The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer.
Nelson, RL, 1982
)
0.72
" The pharmacokinetic parameters of MTX in plasma and CSF were estimated."( Pharmacokinetics of methotrexate in plasma and cerebrospinal fluid.
Abe, T; Ghoda, M; Hori, S; Mori, T; Morikawa, N; Takeyama, M, 1997
)
0.3
" The half-life of MTX in the CSF in the space left by tumor removal exceeded the half-lives of MTX in the plasma and in the ventricular CSF."( Pharmacokinetics of methotrexate in plasma and cerebrospinal fluid.
Abe, T; Ghoda, M; Hori, S; Mori, T; Morikawa, N; Takeyama, M, 1997
)
0.3
" THP concentration was measured by HPLC, and the pharmacokinetic parameters of this drug were estimated in plasma and CSF."( Pharmacokinetics of intra-arterially administered pirarubicin in plasma and cerebrospinal fluid of patients with glioma.
Hori, S; Mori, T; Morikawa, N; Takeyama, M, 1998
)
0.3
" The elimination half-life at steady state of rituximab in all patients was estimated to be 19."( Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies.
Aarden, L; Baars, JW; Beijnen, JH; Huitema, AD; Tran, L, 2010
)
0.36

Compound-Compound Interactions

Two combination phase I trials were undertaken to determine the maximum tolerated dose of CPT-11 in combination with cisplatin and vindesine in patients with advanced non-small cell lung cancer. The effects of alpha-difluoromethylornithine (DFMO; RMI 71782) in combination With Adriamycin were investigated in three animal tumor models.

ExcerptReferenceRelevance
"The anticancer effect of a podophyllotoxin derivative, etoposide (ETOP), and the vinca alkaloids, vincristine (VCR) and vindesine (VDS), on the colony forming efficiency (CFE) of B16 melanoma cells, and the CFE inhibition by the combination with a biscoclaurine alkaloid, Cepharanthine (Ceph) were studied in vitro."( [Enhancement of the effects of anticancer agents on B16 melanoma cells by combination with cepharanthine--I. Alkaloids].
Kubota, K; Kubota, R; Yamada, S, 1992
)
0.49
"In a prospective pilot study 21 patients with advanced squamous cell carcinoma of the head and neck were treated with polychemotherapy and Hyaluronidase combined with radiation."( [Cisplatin, vindesine and hyaluronidase combined with simultaneous radiotherapy of advanced head and neck tumors].
Allmayer, H; Klocker, J; Rab, B; Schumer, J; Tidstrand, J, 1990
)
0.66
"Seventy-two previously untreated patients with localized inoperable non-small cell lung cancer were randomized to a study comparing the efficacy of cis-platinum-vindesine (P-VDS) and of cis-platinum-VP16 (P-VP16), both combined with split-course radiotherapy."( A comparison of cis-platinum-vindesine and cis-platinum-etoposide combined with radiotherapy for previously untreated localized inoperable non-small cell lung cancer.
Holsti, LR; Holsti, P; Mattson, K; Niitamo-Korhonen, S; Pyrhönen, S, 1989
)
0.76
" Four cycles of the regimen I drug combination failed to prolong life due to toxic side effects in every cancer line."( [Effects of alternating chemotherapy with 2 non-cross-resistant drug combinations on human alimentary and breast cancer xenografts in nude mice].
Fujita, F; Fujita, M; Inaba, H; Sakamoto, Y; Shimozuma, K; Taguchi, T; Yamauchi, T, 1987
)
0.27
"The pharmacokinetics of cyclophosphamide (CPH) administered intravenously at doses between 200-400 mg alone or in combination with vindesin (VDS) or cisplatin (cisPt) were studied in 5 patients who had bronchial adenocarcinoma, with normal liver and kidney functions."( Pharmacokinetics of cyclophosphamide administered alone or in combination with vindesin or cisplatin in 5 patients with bronchial adenocarcinoma.
Berger, JA; Chabard, JL; Chollet, P; Lartigue-Mattei, C; Petit, J; Plagne, R; Touzet, C, 1988
)
0.27
"The effects of alpha-difluoromethylornithine (DFMO; RMI 71782) in combination with vindesine or Adriamycin were investigated in three different animal tumor models."( Effects of alpha-difluoromethylornithine alone and combined with adriamycin or vindesine on L1210 leukemia in mice, EMT6 solid tumors in mice, and solid tumors induced by injection of hepatoma tissue culture cells in rats.
Bartholeyns, J; Koch-Weser, J, 1981
)
0.72
"One hundred and seventy-nine previously treated children with acute lymphoblastic leukemia in relapse considered not "resistant" to vincristine (VCR) were randomly allocated to receive reinduction therapy with either vindesine (VND) or VCR, in combination with prednisone and L-asparaginase."( Comparison of the therapeutic response of patients with childhood acute lymphoblastic leukemia in relapse to vindesine versus vincristine in combination with prednisone and L-asparaginase: a phase III trial.
Anderson, J; Chard, R; Chilcote, R; Hammond, D; Krivit, W; Pyesmany, A,
)
0.53
"BD2F1 mice were inoculated ip with 10(6) L1210 leukemia cells and treated with vincristine or vindesine alone or in combination with methotrexate."( Increased schedule-dependent synergism of vindesine versus vincristine in combination with methotrexate against L1210 leukemia.
Chello, PL; Sirotnak, FM,
)
0.61
" Two combination phase I trials were undertaken to determine the maximum tolerated dose of CPT-11 in combination with cisplatin and vindesine in patients with advanced non-small cell lung cancer."( Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
Arioka, H; Eguchi, K; Karato, A; Kunikane, H; Nishio, M; Ohe, Y; Oshita, F; Sasaki, Y; Shinkai, T; Tamura, T, 1994
)
0.69
" Experimental data suggest a synergistic cytotoxic activity of alpha-interferon (alpha-IFN) when combined with cisplatin, mitomycin C and vinca alkaloids."( A phase II study of mitomycin C, vindesine and cisplatin combined with alpha interferon in advanced non-small cell lung cancer.
Bascioni, R; Battelli, N; Battelli, T; Delprete, S; Gasparini, S; Mattioli, R; Pilone, A; Rossini, S; Silva, RR; Zuccatosta, L,
)
0.41
" Larger randomized trials are needed to assess the role of alpha-IFN combined with chemotherapy in advanced NSCLC."( A phase II study of mitomycin C, vindesine and cisplatin combined with alpha interferon in advanced non-small cell lung cancer.
Bascioni, R; Battelli, N; Battelli, T; Delprete, S; Gasparini, S; Mattioli, R; Pilone, A; Rossini, S; Silva, RR; Zuccatosta, L,
)
0.41
" Although the incidence of modest (grade 2) late GI and GU toxicities seem to be increased compared with 3D-CRT alone or in combination with androgen ablation therapy, no severe toxicities were encountered with this regimen."( Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer.
Fuks, Z; Kelly, WK; Lee, H; Leibel, SA; Metz, E; Scher, HI; Schwartz, L; Smart, T; Zelefsky, MJ, 2000
)
0.31
"This communication represents the definitive report of a randomized phase III study comparing cisplatin and carboplatin, in combination with vindesine and mitomycin C in stage IIIB and IV squamous-cell bronchogenic carcinoma."( Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study.
Babović, N; Elezar, E; Gavrilović, D; Jelić, S; Kovacević, S; Kovcin, V; Mitrović, L; Radosavljević, D; Radulović, S; Tomasević, Z, 2001
)
0.74
"To evaluate the result of radiotherapy combined with chemotherapy for advanced nasopharyngeal carcinoma (NPC)."( [Clinical study of advanced nasopharyngeal carcinoma treated with radiotherapy combined with DDP and vindesine].
Liu, H; Liu, M; Mao, Z, 1999
)
0.52
"From August 1996 to October 1997, 64 cases of advanced NPC (stage N2-N3) patients were randomized to receive radiotherapy (RT) alone or RT combined with 2 cycles of chemeotherapy (CT) (cisplatin, vindesine)."( [Clinical study of advanced nasopharyngeal carcinoma treated with radiotherapy combined with DDP and vindesine].
Liu, H; Liu, M; Mao, Z, 1999
)
0.71
"To observe the effects of chemotherapy combined with Chinese herbal medicine (Spleen-Kidney tonifying) in treating advanced tumor patients and on immune parameters."( [Clinical observation on effect of chemotherapy combined with Chinese medicine in treating advanced tumor patients and on immunologic parameters].
Gong, LY; Jiang, CM; Pang, MR, 2001
)
0.31
"One hundred and one advanced tumor patients were randomly divided into the treated group (54 patients) treated by Chinese medicine combined with chemotherapy, and the control group (47 patients) treated by chemotherapy alone."( [Clinical observation on effect of chemotherapy combined with Chinese medicine in treating advanced tumor patients and on immunologic parameters].
Gong, LY; Jiang, CM; Pang, MR, 2001
)
0.31
"Chemotherapy combined with Chinese Spleen-Kidney tonifying drugs could improve the immunologic functions in the advanced tumor patients."( [Clinical observation on effect of chemotherapy combined with Chinese medicine in treating advanced tumor patients and on immunologic parameters].
Gong, LY; Jiang, CM; Pang, MR, 2001
)
0.31
"To evaluate the therapeutic effect of preoperative transcatheter arterial chemoembolization (TACE) combined with short-term systematic chemotherapy in the treatment of advanced Wilms tumor."( A retrospective study of the preoperative treatment of advanced Wilms tumor in children with chemotherapy versus transcatheter arterial chemoembolization alone or combined with short-term systemic chemotherapy.
Huang, Y; Li, MJ; Tang, DX; Tang, HF; Wu, DH; Xu, S; Zhang, YY; Zhou, YB, 2011
)
0.37
" Twenty patients were treated with conventional preoperative chemotherapy (PC group) using vindesine, actinomycin D, and pirarubicin for 4 weeks; 21 patients were treated in the TACE group with preoperative renal arterial chemoembolization using Lipiodol-pirarubicin-vindesine emulsion; and 25 patients were treated with preoperative chemoembolization combined with short-term systematic chemotherapy (T+S) for 2 weeks."( A retrospective study of the preoperative treatment of advanced Wilms tumor in children with chemotherapy versus transcatheter arterial chemoembolization alone or combined with short-term systemic chemotherapy.
Huang, Y; Li, MJ; Tang, DX; Tang, HF; Wu, DH; Xu, S; Zhang, YY; Zhou, YB, 2011
)
0.59
"From our experience, preoperative chemoembolization combined with short-term systematic chemotherapy is able to achieve higher rates of complete tumor resection and relapse-free survival in the treatment of advanced Wilms tumor."( A retrospective study of the preoperative treatment of advanced Wilms tumor in children with chemotherapy versus transcatheter arterial chemoembolization alone or combined with short-term systemic chemotherapy.
Huang, Y; Li, MJ; Tang, DX; Tang, HF; Wu, DH; Xu, S; Zhang, YY; Zhou, YB, 2011
)
0.37
"As rituximab combined with CHOP improves complete remission and overall survival in diffuse large B-cell lymphoma, intensified chemotherapy followed by autologous stem-cell transplantation has also been advocated for high-risk patients."( Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.
Anglaret, B; Belhadj, K; Brechignac, S; Casasnovas, O; Ferme, C; Feugier, P; Fitoussi, O; Gabarre, J; Ghesquieres, H; Gisselbrecht, C; Haioun, C; Herbrecht, R; Janvier, M; Morschhauser, F; Mounier, N; Parrens, M; Salles, G; Tilly, H; Van Den Neste, E; Ysebaert, L, 2011
)
0.37
" Our study suggests that the MTD of idarubicin in combination with HD-MTX, VDS, and PRED, should be 16 mg/m(2) ."( A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.
Brion, A; Chabin, M; Clavert, A; Colombat, P; Cumin, I; Delwail, V; Escoffre-Barbe, M; Gardembas, M; Ingrand, P; Lacotte-Thierry, L; Legouffe, E; Olivier, G; Solal-Celigny, P, 2014
)
0.63
"The purpose of this study is to compare the efficacy and safety of Gefitinib versus VMP in combination with three-dimensional conformal radiotherapy (3D-CRT) for multiple brain metastases from non-small cell lung cancer (NSCLC)."( Comparison of Gefitinib versus VMP in the combination with radiotherapy for multiple brain metastases from non-small cell lung cancer.
Chen, S; Hao, Y; Li, B; Li, L; Liu, C; Ning, F; Wang, F; Yu, Z, 2015
)
0.42
"To investigate the inductive therapeutic effects of imatinib combined with VP low dose regiment on adult patients with Ph-positive acute lymphoblastic leukemia (Ph(+) ALL)."( [Imatinib Combined with VP Low Dose Regiment for Treating Newly Diagnosed Adult Patients with Ph-positive ALL].
Gao, XN; Guo, YL; Han, XP; Jin, XS; Jing, Y; Liu, K; Yao, ZL; Yu, L; Zhang, R, 2015
)
0.42
" Patients could be treated with imatinib combined with chemotherapy for consolidation and maintenance therapy or were treated with allogeneic hematopoietic stem cell transplantation after complete remission."( [Imatinib Combined with VP Low Dose Regiment for Treating Newly Diagnosed Adult Patients with Ph-positive ALL].
Gao, XN; Guo, YL; Han, XP; Jin, XS; Jing, Y; Liu, K; Yao, ZL; Yu, L; Zhang, R, 2015
)
0.42
"In the period of tyrosine kinase inhibitor (TKI), inductive chemotherapy combined with imatinib and low dose VP can obtaine satisfactory CR rate and decrease the toxicity of the traditional drugs."( [Imatinib Combined with VP Low Dose Regiment for Treating Newly Diagnosed Adult Patients with Ph-positive ALL].
Gao, XN; Guo, YL; Han, XP; Jin, XS; Jing, Y; Liu, K; Yao, ZL; Yu, L; Zhang, R, 2015
)
0.42
"To compare the efficacy and safety of BD regimen combined with cyclophosphamide(CTX) and pirarubicin chemotherapy(P-CAD) for patients with relapse/refractory multiple myeloma(MM)."( [Effect of BD Regimen Combined with Cyclophosphamide and Pirarubicin in Treatment of Relapse/Refractory Multiple Myeloma].
Chen, YL; Ma, XH; Qiu, ZY; Ren, CA; Wang, YF; Xu, WJ, 2016
)
0.43
"BD regimen combined with cyclophosphamide and pirarubicin chemotherapy can improve the response rate of patients with relapse/refractory multiple myeloma, and shows the trend of prolonging PFS and survival times."( [Effect of BD Regimen Combined with Cyclophosphamide and Pirarubicin in Treatment of Relapse/Refractory Multiple Myeloma].
Chen, YL; Ma, XH; Qiu, ZY; Ren, CA; Wang, YF; Xu, WJ, 2016
)
0.43
"This is a retrospective, single-center PSM study evaluating the efficacy and safety of chidamide combined with the CHOEP (C-CHOEP) regimen versus the single CHOEP regimen in patients with untreated peripheral T cell lymphomas (PTCL)."( Long-time follow-up of patients with untreated peripheral T cell lymphoma following chidamide combined with cyclophosphamide, epirubicin, vindesine, prednisone, and etoposide therapy: a single-center propensity score-matching study.
Wang, W; Wei, C; Zhang, W; Zhang, Y; Zhao, D; Zhou, D, 2023
)
1.11

Dosage Studied

Vindesine toxicity depends on the dosage and the time of administration. A dosage increase from 3 to 5 mg/m2 vindesine was not tolerated in this combination.

ExcerptRelevanceReference
" Haematologic toxicity is greater in the CMF group, requiring more frequent dosage reductions."( Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen [see comment].
Bonichon, F; Chauvergne, J; Dilhuydy, JM; Durand, M; Mauriac, L, 1992
)
0.28
"Patients with inoperable non-small-cell lung cancer (NSCLC) were randomly assigned to receive one of three dosage regimens: (1) vindesine and cisplatin (VP); (2) mitomycin, vindesine, and cisplatin (MVP); or (3) etoposide and cisplatin alternating with vindesine and mitomycin (EP/VM)."( A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.
Fukuoka, M; Furuse, K; Kawahara, M; Kudoh, S; Masuda, N; Matsui, K; Negoro, S; Ogawara, M; Takada, M; Takifuji, N, 1991
)
0.73
" CDDP was given at a dosage of 60 to 110 mg/m2 every 4 weeks, and VDS at a dosage of 3 mg/m2 3 times weekly."( [Radiotherapy combined with cis-diammine-dichloro platinum (II) plus vindesine in the treatment of non-small cell lung cancer: a comparison with treatment by radiation alone].
Koga, K; Minoda, S; Murai, N; Nishikawa, K, 1990
)
0.51
" Cisplatinum 20 mg/m2 daily X 5 - twice at the interval of 10 days with MTX 25 mg/m2 and Bleomycin 15 mg/m2 weekly X 2 have been used for T3 and T4 Head and Neck Cancers and Cisplatinum in the same dosage and MTX 200 mg twice in 10 days have been used for esophageal cancers."( The impact of combined therapeutic modalities in head, neck, and esophageal cancer.
Advani, SH; Desai, PB; Dinshaw, KA; Gopal, R; Pinto, JM; Saikia, TK; Sharma, S; Swaroop, VS; Vyas, JJ, 1985
)
0.27
" Dosage was based on investigators' estimate of patients' bone marrow reserve."( Vindesine and mitomycin C in metastatic breast cancer. A Southeastern Cancer Study Group Trial.
Einhorn, L; Luedke, DW; Luedke, SL; Lyss, AP; Raney, M, 1989
)
1.72
" The overall toxicity was high, with hematologic, digestive and renal side effects, leading to stop the treatment in 5/25 patients, and to reduce drugs dosage by greater than or equal to 25% in nearly half of the patients."( [Treatment of soft tissue sarcomas in the adult with a combination of vindesine and cisplatin with doxorubicin or epirubicin: a pilot study].
Becouarn, Y; Brunet, R; Bui, BN; Chauvergne, J; Kerbrat, P; Robert, J, 1987
)
0.51
" The analysis at term showed that the developmental toxicity of vindesine depends on the dosage and the time of administration."( Synergistic interaction between vindesine and X-rays in the prenatal development of mice.
Balla, I; Fritz-Niggli, H; Michel, C, 1987
)
0.8
" Reproducible dose-response relationships were developed for vinblastine (VBL) and vindesine (VDS)."( Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse.
Alberts, DS; Dorr, RT, 1985
)
0.49
" Gralla et al combined DVA with DDP in regimens of varying DDP dosage and noted a response rate of about 43%."( A prospective randomized trial of combination vindesine and cisplatin versus single-agent vindesine in advanced non-small cell lung cancer.
Cersosimo, RJ; Faling, LJ; Fofonoff, SA; Hong, WK; Popkin, JD; Snow, MN,
)
0.39
" Her plasma phenytoin level at the time had dropped to 2 microgram/ml despite a recent dosage increase."( Impaired phenytoin bioavailability secondary to cisplatinum, vinblastine, and bleomycin.
Caldwell, KC; Lewis, FB; Lobell, M; Perri, R; Sawchuk, RA; Sylvester, RK, 1984
)
0.27
" It has become evident that DES at a dosage of 3 mg/day carries a significantly higher risk of overall cardiovascular toxicity than does cyproterone acetate, but severe cardiovascular complications did not differ between treatment groups."( Treatment of prostatic cancer: the EORTC experience--preliminary results of prostatic carcinoma trials.
Schroeder, FH, 1984
)
0.27
" Administered dosage of CDDP was in the range of 60-100 mg/m2 (60 mg/m2, 80 mg/m2, 100 mg/m2 per individual)."( [Cis-dichlorodiammine platinum (II) CDDP in the treatment of non-small cell lung cancer].
Eguchi, K; Saijo, N; Sasaki, Y; Shimizu, E; Shinkai, T; Tominaga, K, 1984
)
0.27
" Less neurotoxic and sufficiently effective dosage of VDS is considered to be 2 mg/m2, once weekly."( [A randomized controlled study on vindesine and vincristine in combination with prednisolone in the treatment of adult acute lymphocytic leukemia and blastic crisis of chronic myeloid leukemia].
, 1983
)
0.54
" A dosage increase from 3 to 5 mg/m2 vindesine was not tolerated in this combination."( [Vindesine and adriamycin in the therapy of metastatic breast cancer].
Nagel, GA; Wander, HE, 1982
)
1.45
" The dosage was 3 mg/m2/48 hours every 2 weeks."( Continuous vindesine infusion in advanced head and neck cancer.
Bromer, RH; Byrne, RE; Fofonoff, SA; Hoffer, SM; Hong, WK; Licciardello, JT; Popkin, JD; Strong, MS; Vaughan, CW; Welch, JM, 1983
)
0.66
" Further evaluation of vindesine will require dosage modification."( Sequential phase II studies of chemotherapy for colorectal cancer with 5-fluorouracil and vindesine with or without methyl-1,3 cis(2 chloroethyl)-1-nitrosourea.
Bedikian, AY; Bennetts, RW; Bodey, GP; Karlin, DA; Stroehlein, JR; Valdivieso, M, 1982
)
0.8
" The drug had to be withheld in only three patients: in two cases a low dosage related to individual sensitivity was being used."( Neurological toxicity of vindesine used in combination chemotherapy of 51 human solid tumors.
Bays, R; Claessens, JJ; Debruyne, H; Focan, C; Le Hung, S; Olivier, R, 1981
)
0.57
" Combination therapy with EDX and vinca alkaloids required dosage attenuation but was still markedly more effective."( Effective combination therapy of metastatic murine solid tumors with edatrexate and the vinca alkaloids, vinblastine, navelbine and vindesine.
Otter, GM; Sirotnak, FM, 1994
)
0.49
" This study shows that in NSCLC a dose-response effect does not exist between carboplatin dose intensification and response rate cannot be traced."( Intensified carboplatin regimen with GM-CSF support in non-small cell lung cancer (NSCLC). A Hellenic Co-operative Oncology Group Study (HeCOG).
Athanassiadis, A; Fountzilas, G; Klouvas, G; Kosmidis, P; Mylonakis, N; Nicolaides, C; Pavlidis, N; Samantas, E; Skarlos, D, 1997
)
0.3
" Chemotherapy consisted of three dosage regimens: (1) vindesine and cisplatin (VP); (2) mitomycin, vindesine and cisplatin (MVP); or (3) etoposide and cisplatin alternating with vindesine and mitomycin (EP/VM)."( Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer.
Fukuoka, M; Furuse, K; Kawahara, M; Kodama, N; Kubota, K; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Negoro, S; Ogawara, M; Takada, M; Takifuji, N, 1997
)
0.55
"The CSF AUCs of MTX in the ventricle and the space left by tumor removal increased markedly and in parallel with the MTX dosage increase during osmotic disruption of the blood-brain barrier and intraarterial combination chemotherapy."( Pharmacokinetics of methotrexate in plasma and cerebrospinal fluid.
Abe, T; Ghoda, M; Hori, S; Mori, T; Morikawa, N; Takeyama, M, 1997
)
0.3
" The dose-response relationship for 4C and 1C populations was linear-quadratic at days 14 and 21, respectively."( Effect of vindesine sulfate on the radiation-induced alterations in mouse spermatogenesis: a flow cytometric evaluation.
Jagetia, GC; Jyothi, P; Krishnamurthy, H, 1998
)
0.7
" The 'treatment protocol adherence' was evaluated by recalculation of the ideal protocol dose and its comparison with the actual delivered dosage at each cycle of chemotherapy."( Quality control in multicentric clinical trials. An experience of the EORTC Gynecological Cancer Cooperative Group.
Favalli, G; Pecorelli, S; Renard, J; Van Oosterom, AT; Vantongelen, K; Vermorken, JB, 2000
)
0.31
" The cumulative dosage of epirubicin that carries a 5% risk of cardiotoxicity was lower than previously assumed and was dependent on risks of both cardiotoxicity and overall mortality."( New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Andersen, PK; Cortese, G; Nielsen, D; Nielsen, G; Ryberg, M; Skovsgaard, T, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (7)

ClassDescription
vinca alkaloidA group of indole-indoline dimers which are alkaloids obtained from the Vinca genus of plants, together with semi-synthetic and fully synthetic analogues.
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
organic heterotetracyclic compound
organic heteropentacyclic compound
tertiary alcoholA tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
primary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with ammonia; formula RC(=O)NH2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Vindesine Action Pathway105

Bioassays (143)

Assay IDTitleYearJournalArticle
AID347978Antiproliferative activity against rat LT12 cells ectopic expression of human MDR1 after 48 hrs by XTT assay2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID347981Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID347977Antiproliferative activity against rat LT12 cells after 48 hrs by XTT assay2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID347979Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID132361Percent increase in life span at dose 2 mg/kg/day in 7 mice implanted with P388 leukemia cell line for 1,8,15 scheduled days1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID137486Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intraperitoneally at a dose of 3 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID135652Number of survivors on 60th day at dose 2.5 mg/kg/day in 10 mice implanted with P388 leukemia cell line for 1st scheduled day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID611274Antiproliferative activity against mouse VCR-resistant L1210 cells after 48 hrs by XTT assay2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Phenylimino-10H-anthracen-9-ones as novel antimicrotubule agents-synthesis, antiproliferative activity and inhibition of tubulin polymerization.
AID132550Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia intraperitoneally at a dose of 2 mg/kg per day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID274795Antiproliferative activity against L1210 VCR cells by XTT assay after 48 hrs2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID23271Partition coefficient (logD7.4)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID132553Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia intraperitoneally at a dose of 6 mg/kg per day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID132715Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia intravenously at a dose of 5 mg/kg per day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID137979Number of survivors on 30th day at dose 2.5 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID132363Percent increase in life span at dose 2.5 mg/kg/day in 10 mice implanted with P388 leukemia cell line for 1st scheduled day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID132365Percent increase in life span at dose 2.5 mg/kg/day in 7 mice implanted with P388 leukemia cell line for 1,8,15 scheduled days from Exp-21985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID303698Antiproliferative activity against mouse adriamycin-resistant P388 cells after 48 hrs by XTT assay2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID347980Antiproliferative activity against vincristine-resistance MRP1 negative mouse L1210 cells expressing human MDR1 after 48 hrs by XTT assay2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID135840Number of survivors on 60th day at dose 7 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID494513Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay2010European journal of medicinal chemistry, Aug, Volume: 45, Issue:8
Synthesis, antiproliferative activity and inhibition of tubulin polymerization by 1,5- and 1,8-disubstituted 10H-anthracen-9-ones bearing a 10-benzylidene or 10-(2-oxo-2-phenylethylidene) moiety.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID132548Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia intraperitoneally at a dose of 2.5 mg/kg per day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID137483Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intraperitoneally at a dose of 2.5 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID137989Number of survivors on 30th day at dose 3 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID137649Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intravenously at a dose of 7 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID135672Number of survivors on 60th day at dose 4 mg/kg/day in 10 mice implanted with P388 leukemia cell line for 1st scheduled day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID135649Number of survivors on 60th day at dose 2 mg/kg/day in 10 mice implanted with P388 leukemia cell line for 1st scheduled day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID132545Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia cells intraperitoneally at a dose of 0.30 mg/kg per day for 1-9 scheduled days1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID137662Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intraperitoneally at a dose of 6 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID138146Number of survivors on 30th day at dose 7 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID132372Percent increase in life span at dose 3 mg/kg/day in 10 mice implanted with P388 leukemia cell line1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID137991Number of survivors on 30th day at dose 3 mg/kg/day in 9 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID132539Percent increase in life span at dose 8 mg/kg/day in 10 mice implanted with P388 leukemia cell line1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1480298Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors.
AID137656Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intraperitoneally at a dose of 2.5 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID184451Acute iv toxicity against rat after a dose of injection1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID611273Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Phenylimino-10H-anthracen-9-ones as novel antimicrotubule agents-synthesis, antiproliferative activity and inhibition of tubulin polymerization.
AID274793Antiproliferative activity against LT12 MDR cells by XTT assay after 48 hrs2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID274794Antiproliferative activity against L1210 cells by XTT assay after 48 hrs2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID100820Antiproliferative activity against L1210 tumor cell line2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Novel benzylidene-9(10H)-anthracenones as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID132382Percent increase in life span at dose 5 mg/kg/day in 10 mice implanted with P388 leukemia cell line1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID137642Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intravenously at a dose of 5 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID137488Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intraperitoneally at a dose of 6 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID137485Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intraperitoneally at a dose of 2 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID303694Antiproliferative activity against rat multidrug-resistant L12 cells after 48 hrs by XTT assay2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID611271Antiproliferative activity against rat LT12 cells after 48 hrs by XTT assay2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Phenylimino-10H-anthracen-9-ones as novel antimicrotubule agents-synthesis, antiproliferative activity and inhibition of tubulin polymerization.
AID274796Antiproliferative activity against P388 cells by XTT assay after 48 hrs2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID150964Antiproliferative activity against P388 tumor cell line2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Novel benzylidene-9(10H)-anthracenones as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID274797Antiproliferative activity against P388 ADR cells by XTT assay after 48 hrs2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID137498Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intravenously at a dose of 2.5 mg/kg/day; 0/111985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID138156Number of survivors on 30th day at dose 8 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID303696Antiproliferative activity against mouse vincristine-resistant L1210 cells after 48 hrs by XTT assay2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID137480Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intraperitoneally at a dose of 0.30 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID135655Number of survivors on 60th day at dose 2.5 mg/kg/day in 7 mice implanted with P388 leukemia cell line for 1,8,15 scheduled days from Exp-2; 0/111985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID611275Antiproliferative activity against mouse P388 cells after 48 hrs by XTT proliferation assay2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Phenylimino-10H-anthracen-9-ones as novel antimicrotubule agents-synthesis, antiproliferative activity and inhibition of tubulin polymerization.
AID303695Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID44202Effect on cross resistance of CCRF-CEM cells resistant to vincristine.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID135825Number of survivors on 60th day at dose 6 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID132389Percent increase in life span at dose 6 mg/kg/day in 10 mice implanted with P388 leukemia cell line1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID538369Cytotoxicity against human LNCAP cells2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs.
AID132376Percent increase in life span at dose 4 mg/kg/day in 10 mice implanted with P388 leukemia cell line1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1480299Selectivity index, ratio of cytotoxic activity for HEK293 cells to IC50 for Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors.
AID1480300Selectivity index, ratio of cytotoxic activity for human HeLa cells to IC50 for Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors.
AID135673Number of survivors on 60th day at dose 4 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID135665Number of survivors on 60th day at dose 3 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID494512Antiproliferative activity against vincristine-resistant mouse L1210 cells after 48 hrs by XTT assay2010European journal of medicinal chemistry, Aug, Volume: 45, Issue:8
Synthesis, antiproliferative activity and inhibition of tubulin polymerization by 1,5- and 1,8-disubstituted 10H-anthracen-9-ones bearing a 10-benzylidene or 10-(2-oxo-2-phenylethylidene) moiety.
AID303693Antiproliferative activity against rat L12 cells after 48 hrs by XTT assay2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID137804Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intravenously at a dose of 2.5 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID611276Antiproliferative activity against ADR-resistant mouse P388 cells after 48 hrs by XTT assay2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Phenylimino-10H-anthracen-9-ones as novel antimicrotubule agents-synthesis, antiproliferative activity and inhibition of tubulin polymerization.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID347982Antiproliferative activity against doxorubicin-resistant mouse P388 cells expressing MDR1 protein after 48 hrs by XTT assay2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID132722Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia intravenously at a dose of 7 mg/kg per day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID132359Percent increase in life span at dose 2 mg/kg/day in 10 mice implanted with P388 leukemia cell line1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID100819Antiproliferative activity against L1210 phenotype L1210 VCR tumor cell line2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Novel benzylidene-9(10H)-anthracenones as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID303697Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID138007Number of survivors on 30th day at dose 5 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID137990Number of survivors on 30th day at dose 3 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/91985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID137633Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intravenously at a dose of 3 mg/kg/day; 0/111985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID137811Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intravenously at a dose of 3 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID137820Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intravenously at a dose of 5 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID137658Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intraperitoneally at a dose of 2 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID137998Number of survivors on 30th day at dose 4 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID135989Number of survivors on 60th day at dose 8 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID274942Antituberculosis activity against Mycobacterium tuberculosis H37Rv2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.
AID135654Number of survivors on 60th day at dose 2.5 mg/kg/day in 7 mice implanted with P388 leukemia cell line for 1,8,15 scheduled days from Exp-1; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID137978Number of survivors on 30th day at dose 2 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID132364Percent increase in life span at dose 2.5 mg/kg/day in 7 mice implanted with P388 leukemia cell line for 1,8,15 scheduled days from Exp-11985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID135811Number of survivors on 60th day at dose 5 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID274792Antiproliferative activity against LT12 cells by XTT assay after 48 hrs2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID137826Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intravenously at a dose of 7 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID494514Antiproliferative activity against adriamycin-resistant mouse P388 cells after 48 hrs by XTT assay2010European journal of medicinal chemistry, Aug, Volume: 45, Issue:8
Synthesis, antiproliferative activity and inhibition of tubulin polymerization by 1,5- and 1,8-disubstituted 10H-anthracen-9-ones bearing a 10-benzylidene or 10-(2-oxo-2-phenylethylidene) moiety.
AID132564Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia intravenously at a dose of 2.5 mg/kg per day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1480302Binding affinity to Ebolavirus glycoprotein/matrix protein VP40 at 50 uM incubated for 10 mins by thermal shift assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors.
AID132377Percent increase in life span at dose 4 mg/kg/day in 10 mice implanted with P388 leukemia cell line for 1st scheduled day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID132360Percent increase in life span at dose 2 mg/kg/day in 10 mice implanted with P388 leukemia cell line for 1st scheduled day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID101156Antiproliferative activity against LT12 phenotype LT12 MDR tumor cell line2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Novel benzylidene-9(10H)-anthracenones as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID135651Number of survivors on 60th day at dose 2 mg/kg/day in 7 mice implanted with P388 leukemia cell line for 1,8,15 scheduled days; 0/111985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID134233Acute iv toxicity against Swiss strain of 100 mice after 8 doses of injection1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID494510Antiproliferative activity against multi drug-resistant rat LT12 cells after 48 hrs by XTT assay2010European journal of medicinal chemistry, Aug, Volume: 45, Issue:8
Synthesis, antiproliferative activity and inhibition of tubulin polymerization by 1,5- and 1,8-disubstituted 10H-anthracen-9-ones bearing a 10-benzylidene or 10-(2-oxo-2-phenylethylidene) moiety.
AID135666Number of survivors on 60th day at dose 3 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/91985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1147834Biodistribution in po dosed rat blood using [3H]-labeled drug relative to Iv dosing1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID477295Octanol-water partition coefficient, log P of the compound2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
AID494508Antiproliferative activity against rat LT12 cells after 48 hrs by XTT assay2010European journal of medicinal chemistry, Aug, Volume: 45, Issue:8
Synthesis, antiproliferative activity and inhibition of tubulin polymerization by 1,5- and 1,8-disubstituted 10H-anthracen-9-ones bearing a 10-benzylidene or 10-(2-oxo-2-phenylethylidene) moiety.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID132373Percent increase in life span at dose 3 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID101157Antiproliferative activity against LT12 tumor cell line2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Novel benzylidene-9(10H)-anthracenones as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID132362Percent increase in life span at dose 2.5 mg/kg/day in 10 mice implanted with P388 leukemia cell line1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID132534Percent increase in life span at dose 7 mg/kg/day in 10 mice implanted with P388 leukemia cell line1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID150963Antiproliferative activity against P388 phenotype P388 ADR tumor cell line2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Novel benzylidene-9(10H)-anthracenones as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID135653Number of survivors on 60th day at dose 2.5 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID611272Antiproliferative activity against rat multiple drug-resistant LT12 cells after 48 hrs by XTT assay2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Phenylimino-10H-anthracen-9-ones as novel antimicrotubule agents-synthesis, antiproliferative activity and inhibition of tubulin polymerization.
AID494511Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay2010European journal of medicinal chemistry, Aug, Volume: 45, Issue:8
Synthesis, antiproliferative activity and inhibition of tubulin polymerization by 1,5- and 1,8-disubstituted 10H-anthracen-9-ones bearing a 10-benzylidene or 10-(2-oxo-2-phenylethylidene) moiety.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID134235Acute iv toxicity against mice after a dose of injection1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID137660Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intraperitoneally at a dose of 3 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID132551Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia intraperitoneally at a dose of 3 mg/kg per day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID138134Number of survivors on 30th day at dose 6 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID243422log (1/Km) value for human liver microsome cytochrome P450 3A42005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
AID135650Number of survivors on 60th day at dose 2 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID137653Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intraperitoneally at a dose of 0.30 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,217)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990486 (39.93)18.7374
1990's437 (35.91)18.2507
2000's202 (16.60)29.6817
2010's75 (6.16)24.3611
2020's17 (1.40)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.44 (24.57)
Research Supply Index7.45 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index60.15 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials422 (32.49%)5.53%
Reviews0 (0.00%)6.00%
Reviews91 (7.01%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies154 (11.86%)4.05%
Observational0 (0.00%)0.25%
Observational3 (0.23%)0.25%
Other18 (100.00%)84.16%
Other629 (48.42%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (45)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 [NCT03643276]Phase 35,000 participants (Anticipated)Interventional2018-07-15Recruiting
Young Adult Acute Lymphoid Leukemia (ALL): Intensification of Pediatric AIEOP LLA-2000 Treatment [NCT01156883]76 participants (Actual)Interventional2010-04-30Completed
Cinobufacini Tablets Combined With R-CHOP Protocol (Rituximab + Vindesine + Cyclophosphamide + Epirubicin + Prednisone)/CHOP in Treatment of Diffuse Large B Cell Lymphoma: A Phase II Randomized, Controlled and Multi-center Study [NCT02871869]Phase 2/Phase 3316 participants (Anticipated)Interventional2016-09-30Recruiting
Phase III,Randomized Controlled Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma [NCT02767674]Phase 3258 participants (Anticipated)Interventional2016-05-31Recruiting
A Randomized Trial of the I-BFM-SG for the Management of Childhood Non-B Acute Lymphoblastic Leukemia [NCT00764907]Phase 34,000 participants (Anticipated)Interventional2002-11-30Recruiting
A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma (IELSG 26) [NCT00689845]120 participants (Anticipated)Interventional2007-06-30Recruiting
Study Characterizing the Impact of Different Therapeutic Strategies on Event Occurrence at 2 Years, 5 Years, 10 Years, and 15 Years, According to Prognostic Groups in Patients With Hodgkin Lymphoma [NCT00920153]Phase 3442 participants (Actual)Interventional2008-05-31Terminated(stopped due to Other new drugs)
A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide [NCT00759824]Phase 264 participants (Actual)Interventional2008-09-30Completed
NB2004 Trial Protocol for Risk Adapted Treatment of Children With Neuroblastoma [NCT00410631]Phase 3642 participants (Anticipated)Interventional2004-10-31Recruiting
An Open, Single-arm, Multicenter Study of R-CMOP Protocol for Primary Treatment of Diffuse Large B-cell Lymphoma Based on Cardiac Function Screening [NCT05777369]30 participants (Anticipated)Interventional2023-03-31Not yet recruiting
AIEOP LLA 2000 Multicenter Study for the Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia [NCT00613457]Phase 32,039 participants (Actual)Interventional2000-09-30Completed
German Multicenter Trial for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years With Rituximab for Improvement of Prognosis in CD20 Positive Standard Risk ALL (Amend 2) [NCT00199004]Phase 460 participants (Anticipated)Interventional2004-04-30Completed
Multicenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1) [NCT00199017]Phase 475 participants (Anticipated)Interventional2004-04-30Completed
PHASE III MULTICENTRE TRIAL OF TREATMENT OF NEUROBLASTOMA IN CHILDREN AND ADOLESCENTS [NCT00002802]Phase 3500 participants (Anticipated)Interventional1990-07-31Completed
A Major Randomised Trial to Determine the Value of Cisplatin-Based Chemotherapy For All Patients With Non-Small Cell Lung Cancer [NCT00003240]Phase 31,800 participants (Anticipated)Interventional1995-10-31Active, not recruiting
ALL-BFM 2000 Multi-Center Study for the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia [NCT00430118]Phase 34,559 participants (Actual)Interventional2000-07-31Completed
Modified BFM (Berlin-Frankfurt-Munster)Backbone Therapy for Chinese Children or Adolescents With Newly Diagnosed Lymphoblastic Lymphoma [NCT02845882]Phase 3150 participants (Anticipated)Interventional2016-01-31Active, not recruiting
LBL 2018 - International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma [NCT04043494]Phase 3683 participants (Anticipated)Interventional2019-08-23Recruiting
TREATMENT OF ADULT PATIENTS WITH RELAPSING ACUTE LYMPHOCYTIC LEUKEMIA, A MULTICENTER TRIAL [NCT00002532]Phase 20 participants Interventional1993-01-31Active, not recruiting
A Phase II Trial of Pre-operative Chemoradiotherapy Followed by Surgical Resection in Pancoast Tumors: Initial Report of Japan Clinical Oncology Group Trial (JCOG 9806) [NCT00128037]Phase 275 participants Interventional1999-05-31Completed
A Phase II Study Evaluating the Efficacy and Safety of Bortezomib (Velcade™) Combined With ACVBP Regimen in Patients With Previously Untreated Peripheral T-cell Lymphoma [NCT00136565]Phase 260 participants (Actual)Interventional2006-01-08Completed
A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer [NCT00144053]Phase 3450 participants Interventional2001-04-30Completed
Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma [NCT02987244]Phase 1/Phase 2100 participants (Anticipated)Interventional2016-03-31Recruiting
Trial Protocol for the Treatment of Children With High Risk Neuroblastoma (NB2004-HR) [NCT00526318]360 participants (Anticipated)Interventional2007-01-31Recruiting
Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy (CVD-Protocol) in the Second-Line Therapy of Distant Metastasized Malignant Melanoma [NCT00226473]Phase 4200 participants Interventional2001-09-30Recruiting
Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Non Previously Treated Patients Aged From 60 to 65 Years With Diffuse Large B-Cell Lymphoma [NCT00135499]Phase 3138 participants (Actual)Interventional2001-10-16Terminated(stopped due to Recruitment too low)
Neuroblastoma Study Phase II Study of Various Therapies in Patients With Neuroblastoma [NCT00017225]Phase 20 participants Interventional1997-05-31Completed
Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) [NCT00199082]Phase 4650 participants (Anticipated)Interventional2002-07-31Completed
Multicenter Trial for Treatment of Acute Lymphocytic Leukemia in Adults (Pilot Study 06/99) [NCT00199056]Phase 4225 participants Interventional1999-10-31Completed
A Prospective Phase II Study of Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma [NCT04899570]Phase 220 participants (Anticipated)Interventional2021-04-01Recruiting
German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) [NCT00198991]Phase 41,883 participants (Actual)Interventional2003-04-30Completed
B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents [NCT03206671]Phase 3650 participants (Anticipated)Interventional2017-08-03Recruiting
Treatment Protocol for Relapsed Anaplastic Large Cell Lymphoma of Childhood and Adolescence [NCT00317408]96 participants (Anticipated)Interventional2004-04-30Active, not recruiting
The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenanc [NCT00003728]Phase 31,500 participants (Anticipated)Interventional1998-12-31Active, not recruiting
MULTICENTRE TRIAL OF INTENSIFIED THERAPY FOR ADULT ALL (O5/93) [NCT00002531]Phase 20 participants Interventional1993-01-31Active, not recruiting
A LARGE-SCALE TRIAL EVALUATING ADJUVANT CHEMOTHERAPY AFTER CURATIVE RESECTION OF NON-SMALL CELL LUNG CANCER [NCT00002823]Phase 33,300 participants (Anticipated)Interventional1995-02-28Completed
Treatment Optimization in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment - a Phase IV-trial With a Phase III-part to Evaluate Safety and Efficacy of Ne [NCT02881086]Phase 31,000 participants (Actual)Interventional2016-08-31Active, not recruiting
Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-risk Neuroblastoma [NCT03042429]Phase 3360 participants (Actual)Interventional2007-01-01Completed
PHASE I TRIAL OF HYDROXYUREA FOR SALVAGE OF INCURABLE NON-SMALL CELL LUNG CANCER [NCT00002887]Phase 130 participants (Anticipated)Interventional1995-07-31Active, not recruiting
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. [NCT05049473]Phase 2100 participants (Anticipated)Interventional2014-01-31Recruiting
Study of R-ACVBP and DA-EPOCH-R in Patients With Newly Diagnosed Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma [NCT03018626]Phase 3402 participants (Anticipated)Interventional2017-07-27Recruiting
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia [NCT01117441]Phase 36,136 participants (Actual)Interventional2010-06-30Completed
A Randomized Phase III Study of Chemotherapy and Radiotherapy Versus Radiotherapy Alone as Adjuvant Treatment to Patients With Node Positive Stages IB or IIA Cervix Cancer [NCT00003209]Phase 3700 participants (Anticipated)Interventional1997-12-31Completed
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) [NCT04221035]Phase 3800 participants (Anticipated)Interventional2019-11-05Recruiting
A Randomized Trial Using a Modified COG ABFM Regimen Backbone to Investigate Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) [NCT05681260]Phase 3200 participants (Anticipated)Interventional2023-02-06Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]